Joseph Baar

Hematology | Oncology

11100 Euclid Ave
Cleveland, OH 44106

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.

Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 05, 2023

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Journal: NPJ breast cancer

Published: July 21, 2016

Phase II trial of patupilone in patients with brain metastases from breast cancer.

Phase II trial of patupilone in patients with brain metastases from breast cancer.

Journal: Neuro-oncology

Published: January 29, 2014

MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer.

MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer.

Journal: Human pathology

Published: December 08, 2012

Showing 1-4 of 4

Last Updated: 09/26/2026